75161-15-8

Usage

Uses

Used in Pharmaceutical Industry:
5-Hydroxy-2-phenyl-1-benzofuran-3-carboxylic acid is used as a key intermediate in the synthesis of benzofuran aminoalkyl esters, which possess pharmacological properties. These esters can be further developed into potential therapeutic agents for various medical conditions, making 5-Hydroxy-2-phenyl-1-benzofuran-3-carboxylic acid a valuable building block in the drug discovery process.
Used in Chemical Synthesis:
In the chemical industry, 5-Hydroxy-2-phenyl-1-benzofuran-3-carboxylic acid can be utilized as a starting material for the synthesis of various derivatives and analogs with potential applications in different fields. Its unique structure allows for a wide range of chemical reactions, making it a versatile compound for researchers and chemists to explore and develop new molecules with specific properties and functions.

Upstream product

• 4610-75-7 5-hydroxyl‐2‐phenylbenzofuran-3-carboxylate ethyl ester 
• 98-86-2 acetophenone 
• 106-51-4 p-benzoquinone 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 

Downstream Products

• 7182-32-3 2-phenyl-5-methoxybenzo[b]furan 
• 114829-15-1 4-Dimethylaminomethyl-5-hydroxy-2-phenyl-benzofuran-3-carboxylic acid 2-diethylamino-ethyl ester 
• 114829-22-0 2-Phenyl-3-β-diethylaminoethoxycarboxylic-5-oxybenzofuran 
• 7182-29-8 5-hydroxy-2-phenylbenzofuran 
• 300674-03-7 5-methoxy-2-phenyl-benzofuran-3-carboxylic acid 

Relevant academic research and scientific papers

A kind of benzofuran and benzofuran coumarin derivative and its preparation method and application (by machine translation)

The invention discloses a formula (I), (II), (III), (IV) shown benzofurans and Coumestans derivative and its preparation method, and said styrene and furan and Coumestans derivative compound in the treatment of multi-drug resistant tuberculosis disease in the application. The invention surfactant and furan and Coumestans derivatives are a class of novel structure, the bacteriostatic effect is prominent anti-Mycobacterium tuberculosis compound, it is to Mycobacterium tuberculosis pks13 gene fragment encoding polyketide synthase as the acting target, inhibit the growth and reproduction of microorganisms, in particular inhibiting Mycobacterium tuberculosis in bacterial cell wall synthesis of branch, in the medical field has potential application prospect. (by machine translation)

Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis

Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery. The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids. Small molecules targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compound whose X-ray cocrystal structure has been very recently solved. Its initial inactivity in a serum inhibition titration (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability. Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT. Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.